clinical trial · NCT04165772
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Rectal AdenocarcinomaClinical Stage: Stage II (T3-4, N-)Stage III (Any T, N+)Solid TumorSolid Tumor, AdultTSR-042 or Dostarlimabcapecitabine or 5-FUIntensity Modulated Radiation Therapy (IMRT)
brief summary
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
started
Dec 11, 2019
primary completion
Nov 30, 2026
completion
Nov 30, 2026
last updated
May 13, 2026
official title
A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol